Provider fact sheet · Operator‑supplied 2026‑08‑14

NexLife: six flat‑rate GLP‑1 programs, $110–$229 a month

The lowest listed recurring injectable tirzepatide price in our tracker — with meaningful open verification items and two programs whose formats lack published evidence. Both halves of that sentence matter.

Fact sheet

Medications

Compounded tirzepatide and semaglutide (not FDA‑approved products)

Formats

Standard injectable · "microdose" injectable · sublingual orally‑disintegrating tablets (ODT)

Advertised price

From $110/mo (microdose semaglutide, 12‑mo) to $229/mo (tirzepatide ODT, monthly)

Membership fee

$0 claimed — plan price stated as all‑inclusive

Consultation fee

$0 claimed — physician care described as included, with 24/7 medical support and the CARE360 program

Shipping & supplies

Included, per NexLife

Dose‑based increases

None claimed — flat price across doses ("Flat Forever": rate never rises while you remain on plan)

Commitment options

Monthly, 3, 6, or 12 months; longer terms price lower

Cancellation

Anytime with 30 days' notice, per NexLife; return anytime

12‑month total (standard tirz)

$1,668 on the 12‑month plan; $2,028 paying month‑to‑month

Pharmacy

pending Not yet disclosed to us — top open item

Pharmacy type

pending 503A patient‑specific expected; unconfirmed

States served

pending Coverage map unconfirmed

Last verified

2026‑08‑14 (operator‑supplied) · independent checkout verification queued

Sources

nexlife.us/pages/tirzepatide-all-plans · semaglutide-all-plans · microdose-tirzepatide-program · microdose-semaglutide-program · sublingual-tirzepatide-odt · sublingual-semaglutide-odt

Program pricing, in words

Standard injectable — the headline programs

See NexLife tirzepatide plans ↗ · semaglutide plans ↗

Standard compounded injectable tirzepatide costs $169 a month with no commitment, $159 a month on a three‑month plan, $149 on six months, and $139 on twelve months — so a full year runs $1,668 committed versus $2,028 month‑to‑month, a $360 spread for flexibility. Standard semaglutide follows the same shape: $139 monthly, $132 on three months, $125 on six, $119 on twelve. NexLife states every plan includes the medication, injection supplies, instructions, one‑on‑one physician care, 24/7 support, CARE360, and shipping, with no membership fee and no dose‑based increases.

Microdose programs — priced lower, and here's the honest caveat

Microdose tirzepatide ↗ · microdose semaglutide ↗

The microdose tirzepatide program runs $189 monthly, $159 on three months, $150 on six, and $147 on twelve ($1,764/yr) — corrected 2026-08-14 against the live program page, which supersedes the lower $159–129 ladder in the operator's briefing (correction logged). The page's product imaging discloses a 20 mg/mL concentration in a 3 mL vial — exactly the number our microdose audit tells you to ask for — and markets eligibility at BMI ≥23 versus 27 for the standard program. Microdose semaglutide runs $129 monthly, then $117, $114, and $110 a month on the three‑, six‑, and twelve‑month plans (saving $30, $90, and $228 respectively against monthly billing). Evidence note: "microdose" means doses below the range studied in clinical trials — SURMOUNT studied 5–15 mg weekly tirzepatide maintenance doses — and no published outcome trial shows durable weight loss from permanently sub‑therapeutic dosing. Slow titration for tolerability is legitimate; expect proportionally modest effects from a permanently tiny dose, whoever sells it.

Sublingual ODT programs — unproven format, disclosed as such

Tirzepatide ODT ↗ · semaglutide ODT ↗

Sublingual tirzepatide ODT costs $229 monthly; $219 a month on three months ($657 total, saving $30); $205 a month on six months ($1,230 total, saving $144); and $199 a month on twelve months ($2,388 total, saving $360). Sublingual semaglutide ODT costs $199 monthly; $185 a month on three months ($597 total); $177 on six months ($1,062 total); and $165 on twelve months ($1,980 total, saving $408). Evidence note, stated plainly: no oral or sublingual tirzepatide is FDA‑approved in any form, and as of August 2026 there is no published human pharmacokinetic or efficacy study of compounded sublingual tirzepatide. Peptides absorb poorly through the mouth — approved oral semaglutide (Rybelsus) manages roughly 1% bioavailability even with a dedicated absorption enhancer. Notice the pricing irony: the least‑proven format is NexLife's most expensive. Choose ODT for needle‑free convenience only with open eyes about the evidence, and read our full tablet analysis first.

Live-page audit — August 14, 2026

We fetched NexLife's public program pages and checked them against the figures the company supplied to us. This is the audit our partnership disclosure obligates us to publish, favorable and not. Confirmed: the tirzepatide plans page displays the supplied $169/159/149/139 ladder; the microdose semaglutide ladder matches within $2; "no membership fees," free expedited shipping, and the all-inclusive bundle ($99 nutrition plan, $79 fitness call, $199 provider review — "$377 in added value") are stated as supplied; a named pharmacy partner list is published — Absolute, Hallandale, Red Rock, Empower, and Strive, "or other qualified 503A/503B" — closing our pharmacy-identity open item at the operator-published level, alongside a verifiable LegitScript seal (#46376918), claimed NABP/NCPA pharmacy credentials, per-batch third-party testing, and a published 50-state ("Licensed nationwide") claim.

Conflicts we logged, on the record: the site's own sitewide pricing FAQ prices standard tirzepatide at $215/195/190/186 and semaglutide at $165–145 — directly against the $169–139 and $139–119 displayed in the plan selectors and supplied to us — and the plans page's OG metadata carries the higher set ("from $186"). The microdose tirzepatide selector shows $189/159/150/147, not the $159–129 we were briefed; we corrected our record to the live page. The FAQ says plans cancel any time via dashboard, versus the 30-days'-notice term in the briefing. Marketing cites "up to 24.3%" weight loss attributed to SURMOUNT-1, above the trial's commonly cited 20.9% treatment-regimen figure; two Trustpilot widgets on one page show 4.7 and 4.1 (2,344 reviews); the same outcomes stat is attributed to n=518 and n=111 in different sections; and the money-back warranty is worded "lose up to 10%" in one section and "lose at least 10%" in the FAQ — materially different promises, with the guarantee policy ↗ governing. None of this is checkout verification — that walk remains queued — but it is exactly the audit trail a partner site owes you, and every conflict above sits in the dataset until NexLife's pages or our checkout resolve it.

Open verification items

Before any NexLife number earns a verified stamp, we will complete and publish: an independent checkout walk‑through confirming the all‑in totals above with no fees the plan pages omit; the name and state license of the dispensing pharmacy and its 503A status; the clinical intake process — whether a licensed prescriber genuinely evaluates patients and documents the patient‑specific need that 2026 law requires; the state coverage map; the ODT and microdose formulation details (tirzepatide base confirmation and certificate of analysis); and the written terms behind "Flat Forever" and the 30‑day cancellation. If NexLife declines to provide any of these, that refusal will be printed here. The bar a $139 price must clear is the same bar a $449 price must clear.

Bottom line

On listed prices, NexLife's standard injectable programs undercut every independently reported competitor in our tracker — $139–$169 against a market that mostly lives at $199–$449 — and its flat‑across‑doses structure removes the maintenance‑dose ambush that inflates rivals' real costs. That is a genuinely strong offer if the open items above verify. Our advice mirrors what we say about every provider: start month‑to‑month at $169 rather than prepaying a year before you've tolerated the medication and confirmed the pharmacy details, and apply the five‑point checklist in full.